This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Pharma Clinical Trial Services: World Market 2013-2023

Visiongain is a trading partner with the US Federal Government

CCR Ref number: KD4R6

Table of Contents

1. Executive Summary

1.1 Pharma Clinical Trial Services: World Market Review

1.2 Report Contents

1.3 Research and Analysis Methods

2. An Introduction to Clinical Trial Outsourcing

2.1 A Brief History of Clinical Trials2.2 Clinical Trial Design and Execution2.2.1 Phases of Clinical Trials2.2.1.1 Phase I Trials: First-in-Human Studies2.2.1.2 Phase II Trials: Proof-of-Concept2.2.1.3 Phase III Trials: Preparing for Approval Applications2.2.1.4 Post-Marketing Studies2.2.2 Key Elements of Clinical Trials2.2.3 Common Trial Designs2.2.3.1 Improving Clinical Trial Models Through Adaptive Trial Designs2.3 Clinical Trial Outsourcing2.3.1 Challenges Exist in Conducting Clinical Trials2.3.2 Benefits of Outsourcing

3. The World Pharma Clinical Trial Services Market 2013-2023

3.1 The Pharma Clinical Trial Services Market 2011-2012

3.1.1 Rapid Growth in the Clinical Trial Outsourcing Market 2008-2011

3.1.2 CRO Revenue by Trial Phase 2011

3.1.3 Big Pharma Companies Are the Leading Clients for CROs

3.2 The Pharma Clinical Trial Services Market 2013-2023

3.2.1 What Will Drive Growth in Clinical Trial Outsourcing 2013-2023?

3.2.2 The Pharma Clinical Trial Services Market: Overall Revenue Forecast 2013-2023

3.2.3 Which Market Sector Will Account for Most Revenue 2013-2023?

3.3 Early Phase Clinical Trial Services 2013-2023

3.3.1 Rising Demand for Early Phase Services Throughout the Decade

3.3.2 Biotech Outsourcing to Drive Early Phase Growth

3.4 Late Phase Clinical Trial Services 2013-2023

3.4.1 Late Phase Clinical Trial Services: The Largest Market Sector 2013-2023

3.4.2 Focus on Last-Stage Pipeline Candidates Early in the Decade

4. Pharma Clinical Trial Services: Leading Developed Markets 2013-2023

4.1 Leading National Markets for Pharma Clinical Trial Services 20114.2 Pharma Clinical Trial Services: Leading National Market Forecasts 2013-20234.3 North America as a Destination for Clinical Trials4.3.1 The US: The Largest National Market for Clinical Trial Services 2013-20234.3.1.1 Regulatory Developments to Improve Clinical Trials in the US4.3.2 The US: Clinical Trial Service Revenue Forecast 2013-20234.4 The Outlook for Clinical Trial Services in Western Europe 2013-20234.4.1 Rewriting the Rules for Clinical Trials in the EU4.4.2 Western Europe: Overall Market and Leading National Market Forecasts 2013-20234.4.3 Germany Is the Largest Market for Clinical Trial Services in Western Europe4.4.4 France: Market Forecast 2013-20234.4.5 The UK4.4.5.1 Overcoming Challenges in UK Clinical Trials4.4.5.2 UK Clinical Trial Services Market Forecast 2013-20234.4.6 Italy4.4.7 Spain: Market Forecast 2013-20234.5 Japan Is Being Challenged by Neighbouring Emerging Markets4.5.1 Regulatory Policies Driving and Restraining Growth in Japan4.5.2 Growth for Clinical Trial Services in Japan 2013-2023

5. Pharma Clinical Trial Services: Leading Emerging Markets 2013-2023

5.1 Leading Emerging Markets for Clinical Trial Services 2011

4 of 13

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,926.79 +7.20 0.04%
S&P 500 1,982.25 +0.65 0.03%
NASDAQ 4,521.65 -5.8640 -0.13%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs